Kit for gastric cancer drug sensitivity test

Abstract

The invention relates to the technical field of microbiological detection and analysis, in particular to a gastric cancer drug sensitivity test kit which comprises a substrate, a shell, a culture chamber, a liquid storage module and a central distribution unit. The system controller is used for coordinating the work of the multi-position selection valve and the fluid driving pump, so that accurate sample adding from a specified liquid storage cavity to a target culture cavity is realized. The device has an automatic flow path cleaning function, and cross contamination of medicine is effectively prevented; the integrated environment sensor can monitor and adjust culture conditions in real time; complex drug administration modes such as dynamic concentration gradient and time sequence sample adding are supported. According to the invention, automation of the whole process of drug sensitivity test is realized, and a reliable and efficient detection platform is provided for personalized medication of gastric cancer.

Description

Technical Field

[0001] This invention relates to the field of microbial detection and analysis technology, specifically a kit for gastric cancer drug sensitivity testing. Background Technology

[0002] Drug susceptibility testing, also known as drug sensitivity testing, is a crucial technique in microbiology. Its main purpose is to detect whether pathogens (such as bacteria and fungi) are sensitive to or resistant to one or more antimicrobial drugs, thereby providing clinicians with a scientific basis for precise drug use.

[0003] Current methods for gastric cancer drug sensitivity testing primarily rely on traditional manual techniques, which have significant technical limitations. During drug addition, manual operation makes it difficult to precisely control and dynamically adjust drug concentrations, failing to simulate the real-world drug metabolism environment in vivo, leading to discrepancies between test results and actual clinical efficacy. Regarding maintaining the culture environment, traditional methods lack effective monitoring and control mechanisms for environmental parameters. Key parameters within the culture chamber, such as temperature and pH, are easily affected by external disturbances, directly impacting cancer cell growth and drug sensitivity. Particularly during prolonged culture, the accumulation of cell metabolites leads to continuous deterioration of the culture environment, which traditional techniques struggle to detect and correct in a timely manner. This instability in environmental parameters results in inconsistent cell growth states, poor experimental repeatability, and a lack of comparability between test results from different batches. These technical deficiencies severely restrict the accuracy and practicality of gastric cancer drug sensitivity testing in personalized clinical treatment.

[0004] Therefore, it is necessary to develop a kit for gastric cancer drug sensitivity testing to solve the above problems. Summary of the Invention

[0005] The purpose of this section is to outline some aspects of embodiments of the present invention and to briefly describe some preferred embodiments. Simplifications or omissions may be made in this section, as well as in the abstract and title of this application, to avoid obscuring the purpose of these documents; however, such simplifications or omissions should not be construed as limiting the scope of the invention.

[0006] A reagent kit for gastric cancer drug sensitivity testing includes a substrate and a shell, wherein the substrate has multiple independent culture chambers, and further includes: The liquid storage module contains multiple independent liquid storage chambers for holding different liquids, one of which serves as a flushing chamber; The central distribution unit includes a fluid-driven pump and a multi-position selector valve with a common inlet and multiple outlet ports, the common inlet being connected to the outlet of the liquid storage module via a fluid line; The fluid network consists of microchannels connecting the outlet ports of the multi-position selector valve to the corresponding culture chambers; The system controller, electrically connected to the fluid drive pump and the multi-position selector valve, is configured to control the selection state of the multi-position selector valve and the start / stop and flow rate of the fluid drive pump according to a preset program, so as to draw drug solution from a designated storage chamber and deliver it to a designated culture chamber.

[0007] Preferably, it further includes a sealing unit, which includes a locking block fixedly connected to the bottom of the substrate. The upper end of the locking block is connected to a telescopic block via a spring, the lower end of the telescopic block abuts against a top block, and the lower end of the top block is fixedly connected to the outer shell via a spring. A sealing ring is fixedly connected to the lower end of the sealing plate, and the sealing ring abuts against the upper end of the culture chamber to form a seal. The top block presses the liquid storage chamber against the sealing ring by the elastic force of the spring, thereby improving the sealing effect.

[0008] Preferably, the system further includes a flushing unit, which includes an external flushing pipe. The head of the external flushing pipe is divided into multiple branch pipes that enter the liquid storage chamber for flushing the liquid storage chamber before medication change. A throttle valve is fixedly installed on the external flushing pipe to control the start and stop of the branch pipes. An independent cleaning pipe is provided above the branch pipes and enters the flushing chamber. A throttle valve is fixedly installed on the cleaning pipe to control the start and stop of the cleaning pipe. The flushing unit also includes a sewage pipe. The cleaning pipe, the flushing chamber, and the sewage pipe form a flushing passage under the connection of the multi-position selector valve and the fluid drive pump.

[0009] Preferably, the system controller is further configured to control the fluid drive pump to continuously draw drug solution from a single reservoir and pump it into a selected culture chamber at a constant or varying flow rate, thereby generating a time-varying drug concentration gradient in the culture chamber.

[0010] Preferably, the preset program includes a timing sampling program, and the system controller is configured to: At the first time point, the multi-position selection valve is controlled to select the flow path connected to the first liquid storage chamber and deliver the first drug solution to the first culture chamber; At the second time point, the multi-position selection valve is controlled to select the flow path connected to the second liquid storage chamber and deliver the second drug solution to the first culture chamber or the second culture chamber.

[0011] Preferably, each of the microchannels is further provided with an anti-backflow valve, which is located between the multi-position selector valve and the culture chamber.

[0012] Preferably, a miniature pH sensor is provided at the top of the culture chamber. The miniature pH sensor is fixedly connected to the lower end face of the sealing plate, which is fixedly disposed inside the outer shell. The miniature pH sensor is communicatively connected to the system controller.

[0013] Preferably, the system controller is configured to execute a culture environment conditioning program; the culture environment conditioning program includes: Continuously or intermittently receive detection data from the pH sensor; When the detected data is lower than the preset pH threshold, the culture environment is determined to be acidified; The central distribution unit is triggered to inject alkaline buffer or fresh culture medium into the acidified culture chamber to neutralize acidic metabolites and raise the pH of the culture environment to the standard range.

[0014] Preferably, the system controller is further configured to execute a flow path cleaning procedure; Before the drug solution is pumped into a target culture chamber, the flow path cleaning procedure is performed and includes the following steps: The multi-position selector valve is controlled to select the flow path connected to the sewage pipe; The control opens the second throttle valve and starts the fluid drive pump to pump the cleaning fluid out of the flushing chamber; The cleaning fluid flows along the following path: flushing chamber → common inlet and internal flow channel of the multi-position selector valve → fluid drive pump → current outlet port of the multi-position selector valve → sewage pipe; The common inlet and internal flow channel of the multi-position selector valve and the fluid drive pump are flushed, and the waste liquid carrying residual drug solution is directly discharged into the sewage pipe, thereby preventing cross-contamination of different drugs in the common flow path.

[0015] Preferably, the system controller is further configured to execute a liquid reservoir cleaning procedure; The liquid reservoir cleaning procedure is performed after a drug sensitivity test and includes the following steps: Separate the outlet port of the multi-position selector valve and the microchannel from the culture chamber; Control the opening of the throttle valve one on the branch pipeline; The cleaning fluid enters the storage chamber through the branch pipe to rinse it; The waste liquid after rinsing is discharged through the outlet of the liquid storage chamber → the multi-position selector valve → the fluid drive pump → the microchannel, thereby achieving independent cleaning of the liquid storage chamber.

[0016] The beneficial effects of this invention are: This invention successfully overcomes the technical bottlenecks of traditional drug sensitivity testing, such as cross-contamination of drugs, unstable culture environment, and cumbersome operation procedures. The reagent kit employs a multi-position selector valve and independent flow channel design, physically blocking the risk of contact between different drugs and ensuring the accuracy of test results. The integrated environmental monitoring system can sense the physiological state of the culture chamber in real time and automatically make precise adjustments, providing a long-term stable culture environment for organoids. The automated cleaning process not only effectively eliminates interference from residual drugs but also significantly extends the service life of the equipment. Attached Figure Description

[0017] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the following description of the embodiments will be briefly introduced. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0018] in: Figure 1 This is a schematic diagram of the overall structure of the present invention; Figure 2 This is a structural diagram of the outer casing and sealing unit; Figure 3 for Figure 2 Enlarged view of point A in the middle; Figure 4 This is a schematic diagram of the liquid storage module; Figure 5 A schematic diagram of the central distribution unit; Figure 6 This is a schematic diagram of the rinsing unit. Figure 7 A schematic diagram of the central distribution unit, housing, and substrate; Figure 8 for Figure 7 Enlarged view of point B in the middle; Figure 9 This is a schematic diagram of the sealing unit and the culture chamber. Figure 10 for Figure 9 Enlarged view of point C in the middle; In the picture: 1. Substrate; 2. Outer casing; 30. Liquid storage module; 31. Liquid storage chamber; 31a. First liquid storage chamber; 31b. Second liquid storage chamber; 20. Central distribution unit; 21. Fluid-driven pump; 22. Multi-position selector valve; 23. System controller; 24. Anti-backflow valve; 25. pH sensor; 4. Culture chambers; 4a. First culture chamber; 4b. Second culture chamber; 5. Sealing unit; 51. Clamping block; 52. Spring 1; 53. Telescopic block; 54. Spring 2; 55. Top block; 56. Sealing ring; 57. Sealing plate; 6. Flushing unit; 61. External flushing pipe; 62. Cleaning pipe; 63. Throttling valve II; 64. Throttling valve I; 65. Branch pipe; 66. Sewage pipe; 67. Flushing chamber; 7. Microchannels. Detailed Implementation

[0019] To make the objectives, features, and advantages of this invention more apparent and understandable, the technical solutions of the embodiments of this invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the embodiments described below are only some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0020] Example: like Figures 1-10 As shown, a gastric cancer drug sensitivity test kit includes a substrate 1 and a shell 2. The substrate 1 has multiple independent culture chambers 4, and also includes: The liquid storage module 30 contains multiple independent liquid storage chambers 31 for holding different liquids, one of which serves as a flushing chamber 67. The central distribution unit 20 includes a fluid-driven pump 21 and a multi-position selector valve 22 with a common inlet and multiple outlet ports. The common inlet is connected to the outlet of the liquid storage module 30 via a fluid pipeline. The fluid network consists of microchannels 7 that connect the outlet ports of the multi-position selector valve 22 to the corresponding culture chamber 4. The system controller 23 is electrically connected to the fluid drive pump 21 and the multi-position selector valve 22, and is configured to control the selection state of the multi-position selector valve 22 and the start, stop and flow rate of the fluid drive pump 21 according to a preset program, so as to draw out the drug solution from the designated storage chamber 31 and deliver it to the designated culture chamber 4.

[0021] This invention includes a substrate 1 serving as a support base and a housing 2 providing protection and support. Multiple independent culture chambers 4 are mounted on the substrate 1 to hold gastric cancer organoids or tissue sections from patients, serving as areas for drug sensitivity testing. A liquid storage module 30 is connected to a fluid network via an interface and contains multiple independent liquid storage chambers 31 for holding different anticancer drugs, culture media, buffer solutions, etc. One of the liquid storage chambers 31 is specifically designated as a rinsing chamber 67 for holding washing solutions (such as PBS buffer).

[0022] The fluid distribution device is a central distribution unit 20, consisting of a high-precision fluid-driven pump 21 and a multi-position selector valve 22 with a common inlet and multiple outlet ports. The common inlet of the multi-position selector valve 22 is connected to the main outlet of the liquid storage module 30 via a fluid pipeline. A fluid network composed of microchannels 7 connects each outlet port of the multi-position selector valve 22 to its corresponding culture chamber 4. The control center of the entire system is the system controller 23, which is electrically connected to the fluid-driven pump 21 and the multi-position selector valve 22, and stores preset programs to coordinate the entire sample addition process.

[0023] When it is necessary to add a drug to a specific culture chamber 4, the system controller 23 issues an instruction according to a preset program. For example, when it is necessary to add drug H from the first reservoir 31a (one of a plurality of culture chambers 4, referred to as the first culture chamber 4a for convenience) to the first culture chamber 4a (the first culture chamber 4a is one of a plurality of culture chambers 4, referred to as the first culture chamber 4a for convenience), the controller first drives the multi-position selector valve 22 to rotate, so that its common inlet is precisely aligned with the flow path connected to the first reservoir 31a. Subsequently, the fluid drive pump 21 is started to accurately extract the set volume of drug H. Driven by the pump, drug H flows through the common inlet and internal channel of the multi-position selector valve 22, and then through the currently selected outlet port and the corresponding microchannel 7, and is finally delivered to the target first culture chamber 4a without loss. By highly integrating complex fluid distribution functions, fully automated and precise sample addition is achieved from "multiple drug sources" to "multiple culture units," completely eliminating reliance on tedious manual operations and improving experimental efficiency. Simultaneously, the mechanical flow path switching via the multi-position selection valve 22 ensures, from a physical structure perspective, that different drugs use independent flow paths, fundamentally eliminating the risk of cross-contamination between drugs and improving the accuracy of test results.

[0024] Specifically, the system controller 23 is further configured to control the fluid drive pump 21 to continuously draw drug solution from a single reservoir 31 and pump it into a selected culture chamber 4 at a constant or varying flow rate, thereby generating a time-varying drug concentration gradient within the culture chamber 4.

[0025] The system controller 23 controls the fluid-driven pump 21 to continuously draw drug solution from a single reservoir 31 (such as the first reservoir 31a, containing drug H) at an extremely low and constant flow rate and pump it into a selected first culture chamber 4a. With the continuous injection of drug solution, the concentration of drug H in the first culture chamber 4a increases linearly from zero, thereby creating a dynamic environment within the chamber where the concentration changes continuously over time. This allows for detailed study of the adaptive response, resistance activation dynamics, and dose-cumulative effects of cancer cells during the slow escalation of drug concentration, providing dynamic data that more closely approximates the actual situation in patients for assessing the drug's onset threshold, optimal dosing window, and strategies to delay resistance.

[0026] Specifically, the preset program includes a timing sampling program, and the system controller 23 is configured as follows: At the first time point, the control multi-position selection valve 22 selects the flow path connected to the first liquid storage chamber 31a and delivers the first drug solution to the first culture chamber 4a; At the second time point, the control multi-position selection valve 22 selects the flow path connected to the second liquid storage chamber 31b and delivers the second drug solution to the first culture chamber 4a or the second culture chamber 4b.

[0027] The system controller 23 can execute complex time-sequential sample loading procedures. For example, at a first time point (e.g., 24 hours after the start of culture), it controls the multi-position selection valve 22 to select the flow path connected to the first reservoir 31a, delivering a first drug solution (e.g., a conventional chemotherapy drug) to the first culture chamber 4a. At a second time point (e.g., 72 hours after the start of culture), it controls the multi-position selection valve 22 to select the flow path connected to the second reservoir 31b, delivering a second drug solution (e.g., a specific targeted drug) to the same first culture chamber 4a. This system can accurately simulate clinical "combination therapy" or "sequential therapy," and is used to study the synergistic, additive, or antagonistic effects of the order of drug administration on the final efficacy, providing a crucial experimental platform and decision-making basis for developing personalized and optimized combination therapy regimens.

[0028] Specifically, a miniature pH sensor 25 is provided on the top of the culture chamber 4. The miniature pH sensor 25 is fixedly connected to the lower end face of the sealing plate 57. The sealing plate 57 is fixedly installed inside the outer shell 2. The miniature pH sensor 25 is communicatively connected to the system controller 23.

[0029] System controller 23 is configured to execute a culture environment conditioning procedure; the culture environment conditioning procedure includes: Continuously or intermittently receive detection data from pH sensor 25; When the detection data is lower than the preset pH threshold, the culture environment is determined to be acidified; The central distribution unit 20 is triggered to inject alkaline buffer or fresh culture medium into the acidified culture chamber 4 to neutralize acidic metabolites and raise the pH of the culture environment to the standard range.

[0030] At the top of each culture chamber 4, a miniature pH sensor 25 is integrated to monitor changes in the pH of the culture microenvironment in real time.

[0031] The system controller 23 is configured to execute an intelligent culture environment regulation program. It continuously or periodically receives detection data from each micro pH sensor 25. When the system determines that the pH detection data of a certain culture chamber 4 (e.g., the second culture chamber 4b) is consistently lower than a preset threshold (e.g., pH 6.8), it determines that the environment of that chamber has become acidic due to cell metabolism. Subsequently, the controller automatically triggers the central distribution unit 20 to inject a quantitative amount of alkaline buffer or fresh culture medium into the acidified second culture chamber 4b. This automatically and promptly neutralizes the acidic waste produced by cell metabolism, rapidly raising and stabilizing the pH value of the culture environment within the physiological standard range, effectively avoiding cell growth inhibition or death caused by environmental acidification itself, and ensuring that the observed changes in cell activity truly reflect the pharmacological effects of the drug. At the same time, through this closed-loop feedback control, it ensures that all culture chambers are in an optimal and consistent growth environment throughout the entire long-term experiment, significantly eliminating experimental errors introduced by environmental fluctuations, and greatly improving the reliability, repeatability, and comparability between different batches of experimental data.

[0032] Specifically, it also includes a flushing unit 6, which includes an external flushing pipe 61. The head of the external flushing pipe 61 is divided into multiple branch pipes 65 that lead into the liquid storage chamber 31 for flushing the liquid storage chamber 31 before changing the medication. At the same time, a throttle valve 64 is fixedly installed on the external flushing pipe 61 to control the start and stop of the branch pipes 65. An independent cleaning pipe 62 is provided above the branch pipes 65. The cleaning pipe 62 leads into the flushing chamber 67. A throttle valve 63 is fixedly installed on the cleaning pipe 62 to control the start and stop of the cleaning pipe 62. The flushing unit 6 also includes a sewage pipe 66. The cleaning pipe 62, the flushing chamber 67 and the sewage pipe 66 form a flushing passage under the connection of the multi-position selector valve 22 and the fluid drive pump 21.

[0033] Each microchannel 7 is also equipped with an anti-backflow valve 24, which is located between the multi-position selector valve 22 and the culture chamber 4.

[0034] System controller 23 is also configured to execute flow path cleaning procedures; Before the drug solution is pumped into a target culture chamber 4, a flow path cleaning procedure is performed, which includes the following steps: The multi-position selector valve 22 controls the flow path connected to the sewage pipe 66; The control opens the throttle valve 63 and starts the fluid drive pump 21 to pump the cleaning fluid out of the flushing chamber 67; The cleaning fluid flows along the following path: flushing chamber 67 → common inlet and internal flow channel of multi-position selector valve 22 → fluid drive pump 21 → current outlet port of multi-position selector valve 22 → sewage pipe 66; The common inlet of the multi-position selector valve 22, its internal flow channel, and the fluid drive pump 21 are flushed, and the waste liquid carrying residual drug solution is directly discharged into the sewage pipe 66, thereby preventing cross-contamination of different drugs in the common flow path.

[0035] System controller 23 is also configured to execute a cleaning procedure for reservoir 31; The cleaning procedure for reservoir 31 is performed after a drug sensitivity test and includes the following steps: Separate the outlet port of the multi-position selector valve 22 and the microchannel 7 from the culture chamber 4; Control the opening of the throttle valve 64 on branch pipe 65; The cleaning fluid enters the storage chamber 31 through the branch pipe 65 to rinse it; The waste liquid after rinsing is discharged through the path of outlet of storage chamber 31 → multi-position selector valve 22 → fluid drive pump 21 → microchannel 7, thereby achieving independent cleaning of storage chamber 31.

[0036] Before pumping new drug solution into the target culture chamber 4 (such as the second culture chamber 4b), the system prioritizes flow path cleaning. The controller controls the multi-position selector valve 22 to select the flow path connected to the wastewater pipe 66 and opens the second throttle valve 63, starting the fluid drive pump 21. The cleaning solution is pumped out from the flushing chamber 67, flowing through the following path: flushing chamber 67 → common inlet and internal flow channel of multi-position selector valve 22 → fluid drive pump 21 → current outlet port of multi-position selector valve 22 → wastewater pipe 66. This "pre-use purification" of the common flow path thoroughly removes any residual drug from the common flow path of multi-position selector valve 22 and fluid drive pump 21, ensuring physical isolation of different drugs during transport.

[0037] The anti-backflow valve 24 installed on each microchannel 7 automatically closes after pumping stops using its mechanical structure (such as a duckbill valve), preventing the liquid in the culture chamber 4 from flowing back into the microchannel 7 and the common flow path due to pressure changes or capillary action. This effectively avoids cross-contamination between the culture chambers 4 and contamination of the central flow path by the contents, providing an independent, unidirectional fluid barrier for each culture chamber 4, further strengthening the system's anti-contamination system.

[0038] After a drug sensitivity test, the system performs a cleaning of the storage chamber 31. First, the outlet port of the multi-position selector valve 22 and the microchannel 7 are physically separated from the culture chamber 4, forming an independent cleaning circuit. Then, the system controller 23 opens the throttle valve 64 on a specific branch pipe 65, allowing the cleaning solution to enter the storage chamber 31 under pressure through the branch pipe 65, flushing its inner wall. The waste liquid after flushing is discharged to the waste liquid collection device via the following path: outlet of storage chamber 31 → multi-position selector valve 22 → fluid drive pump 21 → microchannel 7. This flushing of the storage chamber 31 effectively removes residual drug solution, preventing crystallization, denaturation, or microbial growth. This allows the storage module 30 to be cleaned safely and thoroughly, preparing it for the next experiment, extending the potential lifespan of consumables and reducing costs.

[0039] Specifically, it also includes a sealing unit 5, which includes a locking block 51. The locking block 51 is fixedly connected to the bottom of the substrate 1. The upper end of the locking block 51 is connected to a telescopic block 53 via a spring 52. The lower end of the telescopic block 53 abuts against a top block 55. The lower end of the top block 55 is fixedly connected to the outer shell 2 via a spring 54. The lower end of the sealing plate 57 is fixedly connected to a sealing ring 56. The sealing ring 56 abuts against the upper end of the culture chamber 4 to form a seal. The top block 55 presses the liquid storage chamber 31 against the sealing ring 56 through the elastic force of the spring 54, thereby improving the sealing effect.

[0040] The locking block 51 is fixed to the bottom of the substrate 1 and pushes the telescopic block 53 upward by the spring 52. The lower end of the telescopic block 53 is in contact with the top block 55, which is connected to the outer shell 2 by the spring 54. The sealing ring 56 at the lower end of the sealing plate 57 fits tightly with the upper opening of the culture chamber 4, forming the first static seal. At the same time, under the continuous elastic force of the spring 54, the top block 55 presses the outlet end face of the liquid storage chamber 31 of the liquid storage module 30 against the sealing ring 56, forming the second dynamic sealing interface (designed as a detachable separation mode, the substrate 1 and the culture chamber 4 can be removed from the outer shell 2, and after the culture chamber 4 is installed, it abuts against the sealing ring 56 on the sealing plate 57 to form a seal).

[0041] The sealing system of “sealing plate 57-sealing ring 56-culture chamber 4” greatly improves the overall sealing reliability of the system under long-term culture and fluid pressure.

[0042] The elastic design of springs 52 and 54 provides continuous and flexible pressure, which can automatically compensate for component manufacturing tolerances, installation errors, and wear that may occur with long-term use, ensuring the durability and consistency of the sealing effect.

[0043] The workflow is as follows: I. Preparation Stage: Sample loading: The operator distributes the gastric cancer organoid tissue samples into the various culture chambers 4 on the substrate 1; Reagent preparation: Ensure that the multiple internal reservoirs 31 are respectively loaded with different anticancer drugs, culture media and buffer solutions, wherein a specific reservoir 31 serves as a rinsing chamber 67 loaded with cleaning solution; Sealing detection: The sealing unit 5 automatically completes the sealing docking. Through the synergistic action of spring 1 52 and spring 2 54, the sealing ring 56 forms a double seal with the culture chamber 4 and the liquid storage chamber 31 (the sealing plate 57 is equipped with an air valve at the position of the culture chamber 4 to balance the air pressure when filling the drug).

[0044] II. Flow path purification stage: Flow path selection: The system controller 23 controls the multi-position selector valve 22 to rotate to the sewage pipe 66 connection position; Cleaning execution: Open throttle valve 63 and start fluid drive pump 21 to pump the cleaning fluid in flushing chamber 67 into the flow path system; Purification path: The cleaning fluid flows sequentially through the common inlet of the multi-position selector valve 22, the internal flow channel, the fluid drive pump 21, and the current outlet port, and is finally discharged into the sewage pipe 66; Effectiveness verification: Thorough cleaning of the shared flow path ensures no drug residues or risk of cross-contamination.

[0045] III. Sampling and Testing Phase: Drug dispensing: The system controller 23 controls the multi-position selection valve 22 to select the reservoir 31 corresponding to the target drug according to the preset program; Precise sample addition: The fluid-driven pump 21 precisely extracts the drug solution at a preset flow rate and volume, and delivers it to the designated culture chamber 4 through the microchannel 7; Backflow prevention: The backflow prevention valve 24 on the microchannel 7 ensures unidirectional liquid flow and prevents cross-contamination between culture chambers; Advanced mode: Supports complex dosing protocols such as dynamic concentration gradient generation and time-sequential sample addition.

[0046] IV. Real-time Environmental Monitoring Phase: Continuous monitoring: A miniature pH sensor 25 integrated into the top of culture chamber 4 monitors culture environment parameters in real time; Intelligent judgment: The system controller 23 continuously receives sensor data and automatically judges that the environment is acidified when the pH value is lower than the set threshold; Automatic adjustment: Immediately triggers the central dispensing unit 20 to inject buffer solution or fresh culture medium into the target chamber; Environmental maintenance: Quickly restore pH value to the physiological standard range to ensure stable testing environment.

[0047] V. Post-Experiment Maintenance Phase: System separation: Physically disconnect the outlet port of the multi-position selector valve 22 and the microchannel 7 from the culture chamber 4; Storage chamber cleaning: Open the throttle valve 64 on the corresponding branch pipe 65 and inject the cleaning fluid into the storage chamber 31 that needs to be cleaned; Waste liquid discharge: The flushed waste liquid is completely discharged through the path of the outlet of the storage chamber 31, the multi-position selector valve 22, the fluid drive pump 21 and the microchannel 7; Equipment maintenance: Complete a thorough cleaning of all flow paths and reservoir 31 to prepare for the next experiment.

[0048] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of protection claimed by the present invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.

Claims

1. A reagent kit for gastric cancer drug sensitivity testing, comprising a substrate (1) and a shell (2), wherein the substrate (1) is provided with a plurality of independent culture chambers (4), characterized in that, Also includes: The liquid storage module (30) contains multiple independent liquid storage chambers (31) for holding different liquids, one of which serves as a flushing chamber (67). The central distribution unit (20) includes a fluid-driven pump (21) and a multi-position selector valve (22) having a common inlet and multiple outlet ports, the common inlet being connected to the outlet of the liquid storage module (30) via a fluid line; The fluid network consists of microchannels (7) that connect the outlet ports of the multi-position selector valve (22) to the corresponding culture chamber (4); The system controller (23), electrically connected to the fluid drive pump (21) and the multi-position selector valve (22), is configured to control the selection state of the multi-position selector valve (22) and the start / stop and flow rate of the fluid drive pump (21) according to a preset program, so as to draw out the drug solution from the designated storage chamber (31) and deliver it to the designated culture chamber (4).

2. The kit for gastric cancer drug sensitivity testing according to claim 1, characterized in that, It also includes a sealing unit (5), which includes a locking block (51). The locking block (51) is fixedly connected to the bottom of the substrate (1). The upper end of the locking block (51) is connected to a telescopic block (53) via a spring (52). The lower end of the telescopic block (53) abuts against the top block (55). The lower end of the top block (55) is fixedly connected to the outer shell (2) via a spring (54). The lower end of the sealing plate (57) is fixedly connected to a sealing ring (56). The sealing ring (56) abuts against the upper end of the culture chamber (4) to form a seal. The top block (55) presses the liquid storage chamber (31) against the sealing ring (56) by the elastic force of the spring (54) to improve the sealing effect.

3. The reagent kit for gastric cancer drug sensitivity testing according to claim 1, characterized in that, It also includes a flushing unit (6), which includes an external flushing pipe (61). The head of the external flushing pipe (61) is divided into multiple branch pipes (65) that enter into the liquid storage chamber (31) for flushing the liquid storage chamber (31) before changing the medicine. At the same time, a throttle valve (64) is fixedly installed on the external flushing pipe (61) to control the start and stop of the branch pipes (65). An independent cleaning pipe (62) is provided above the branch pipes (65). The cleaning pipe (62) enters into the flushing chamber (67). A throttle valve (63) is fixedly installed on the cleaning pipe (62) to control the start and stop of the cleaning pipe (62). The flushing unit (6) also includes a sewage pipe (66). The cleaning pipe (62), the flushing chamber (67) and the sewage pipe (66) form a flushing passage under the connection of the multi-position selector valve (22) and the fluid drive pump (21).

4. The reagent kit for gastric cancer drug sensitivity testing according to claim 1, characterized in that, The system controller (23) is further configured to control the fluid drive pump (21) to continuously draw drug solution from a single reservoir (31) and pump it into a selected culture chamber (4) at a constant or varying flow rate, thereby generating a drug concentration gradient that varies over time in the culture chamber (4).

5. The reagent kit for gastric cancer drug sensitivity testing according to claim 1, characterized in that, The preset program includes a timing sampling program, and the system controller (23) is configured as follows: At the first time point, the multi-position selection valve (22) is controlled to select the flow path connected to the first liquid storage chamber (31a) and deliver the first drug solution to the first culture chamber (4a); At the second time point, the multi-position selection valve (22) is controlled to select the flow path connected to the second liquid storage chamber (31b) and deliver the second drug solution to the first culture chamber (4a) or the second culture chamber (4b).

6. The kit for gastric cancer drug sensitivity testing according to claim 1, characterized in that, Each of the microchannels (7) is also provided with an anti-backflow valve (24), which is located between the multi-position selector valve (22) and the culture chamber (4).

7. The kit for gastric cancer drug sensitivity testing according to claim 1, characterized in that, The top of the culture chamber (4) is provided with a micro pH sensor (25), which is fixedly connected to the lower end face of the sealing plate (57). The sealing plate (57) is fixedly installed inside the outer shell (2), and the micro pH sensor (25) is communicatively connected to the system controller (23).

8. The kit for gastric cancer drug sensitivity testing according to claim 5, characterized in that, The system controller (23) is configured to execute a culture environment conditioning procedure; the culture environment conditioning procedure includes: Continuously or intermittently receive detection data from the pH sensor (25); When the detected data is lower than the preset pH threshold, the culture environment is determined to be acidified; The central distribution unit (20) is triggered to inject alkaline buffer or fresh culture medium into the acidified culture chamber (4) to neutralize the acidic metabolites and raise the pH of the culture environment to the standard range.

9. The kit for gastric cancer drug sensitivity testing according to claim 3, characterized in that, The system controller (23) is also configured to execute a flow path cleaning procedure; Before the drug solution is pumped into a target culture chamber (4), the flow path cleaning procedure is performed and includes the following steps: The multi-position selector valve (22) is controlled to select the flow path connected to the sewage pipe (66); The control opens the second throttle valve (63) and starts the fluid drive pump (21) to pump the cleaning fluid out of the flushing chamber (67); The cleaning fluid flows along the following path: flushing chamber (67) → common inlet and internal flow channel of multi-position selector valve (22) → fluid drive pump (21) → current outlet port of multi-position selector valve (22) → sewage pipe (66); The common inlet and internal flow channel of the multi-position selector valve (22) and the fluid drive pump (21) are flushed, and the waste liquid carrying residual drug solution is directly discharged into the sewage pipe (66) to prevent cross-contamination of different drugs in the common flow path.

10. The kit for gastric cancer drug sensitivity testing according to claim 9, characterized in that, The system controller (23) is also configured to perform a cleaning procedure for the reservoir (31); The cleaning procedure for the reservoir (31) is performed after a drug sensitivity test and includes the following steps: Separate the outlet port of the multi-position selector valve (22) and the microchannel (7) from the culture chamber (4); Control the opening of the throttle valve (64) on the branch pipe (65); The cleaning fluid enters the storage chamber (31) through the branch pipe (65) to rinse it; The waste liquid after rinsing is discharged through the outlet of the liquid storage chamber (31) → the multi-position selector valve (22) → the fluid drive pump (21) → the microchannel (7), thereby realizing independent cleaning of the liquid storage chamber (31).

Images